AspenBio Outlines Steps For FDA 510(k) Clearance Of AppyScore(TM), The First Blood-Based Screen/Triage Test For Human Appendicitis

AspenBio Pharma, Inc. (Nasdaq: APPY), an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for animals and humans, has outlined plans for submitting its final data package to the United States Food and Drug Administration (”FDA”) for market approval of AppyScore(TM), the first blood based screen/triage test for human appendicitis. [click link for full article]

More: continued here

Filed under: GastroIntestinal / Gastroentorology on December 29th, 2007